Showing results (101-110 of 402) with videos related to

Sort By:
Pageof 41
Critical Reviews in Oncology/Hematology|April 20, 2024
What is the role of physical exercise in the era of cancer prehabilitation? A systematic reviewNicole Del Bianco, Anita Borsati, Linda Toniolo, et al.
Expert Opinion on Pharmacotherapy|March 12, 2013
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicineSara Pilotto, Umberto Peretti, Silvia Novello, et al.
Expert Review of Anticancer Therapy|June 19, 2013
Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectivesMatteo Santoni, Michele De Tursi, Alessandra Felici, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 24, 2021
Exercise prehabilitation in lung cancer: Getting stronger to recover fasterAlice Avancini, Alessandro Cavallo, Ilaria Trestini, et al.
Cancers|May 14, 2020
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future PerspectivesMiriam Grazia Ferrara, Vincenzo Di Noia, Ettore D'Argento, et al.
Cancer|June 20, 2007
Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trialsEmilio Bria, Michele Milella, Alain Gelibter, et al.
Pathogens (Basel, Switzerland)|October 27, 2023
Natural History and Hepatitis B Virus Surface Antigen (HBsAg) Spontaneous Seroclearance in Hepatitis B Virus e-Antigen (HBeAg)-Negative Patients with Inactive Chronic Infection: A Multicenter Regional Study from South ItalyMichele Barone, Andrea Iannone, Martino Mezzapesa, et al.
World Journal of Gastroenterology|May 7, 2015
Metastatic pancreatic cancer: Is there a light at the end of the tunnel?Vanja Vaccaro, Isabella Sperduti, Sabrina Vari, et al.
Blood|August 16, 2003
Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosisBing Z Carter, Steven M Kornblau, Twee Tsao, et al.
Expert Opinion on Investigational Drugs|June 13, 2015
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancerSara Pilotto, Silvia Novello, Umberto Peretti, et al.
Pageof 41